Effect of recombinant human growth hormone on adrenocortical function, and on sodium and potassium homeostasis

J. Howard Pratt, Munro Peacock, David P. Henry

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In the present study we examined the effect of treatment with recombinant human growth hormone (rhGH) on adrenocortical secretory function, as well as sodium and potassium balance. rhGH, 100 μg/kg per day, was given for 4 days. Both glucocorticoid and androgen secretion were unaffected by treatment as evidence by unchanged levels of cortisol and dehydroepiandrosterone-sulfate. rhGH resulted in retention of sodium and potassium and a decrease in serum potassium concentration, but neither aldosterone plasma levels nor urinary excretion rates changed until after treatment. During the rhGH washout phase, a natriuresis ensued, but this occurred slowly possibly in part because a higher serum potassium stimulated aldosterone secretion. In summary, short-term treatment with rhGH had no immediate effect on adrenocortical function, but caused pronounced retention of electrolytes. In the posttreatment period, there were increases in aldosterone secretion accompanied by delayed recovery from the retention of sodium.

Original languageEnglish
Pages (from-to)36-42
Number of pages7
JournalPharmacology
Volume47
Issue number1
DOIs
StatePublished - 1993

Fingerprint

Human Growth Hormone
Growth Hormone
Potassium
Homeostasis
Sodium
Aldosterone
Dehydroepiandrosterone Sulfate
Natriuresis
Serum
Electrolytes
Glucocorticoids
Androgens

Keywords

  • Adrenal cortex
  • Aldosterone
  • Cortisol
  • Dehydroepiandrosterone-sulfate
  • Growth hormone

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of recombinant human growth hormone on adrenocortical function, and on sodium and potassium homeostasis. / Pratt, J. Howard; Peacock, Munro; Henry, David P.

In: Pharmacology, Vol. 47, No. 1, 1993, p. 36-42.

Research output: Contribution to journalArticle

@article{07a7c0f16b594f57a0edf06bfb94cf63,
title = "Effect of recombinant human growth hormone on adrenocortical function, and on sodium and potassium homeostasis",
abstract = "In the present study we examined the effect of treatment with recombinant human growth hormone (rhGH) on adrenocortical secretory function, as well as sodium and potassium balance. rhGH, 100 μg/kg per day, was given for 4 days. Both glucocorticoid and androgen secretion were unaffected by treatment as evidence by unchanged levels of cortisol and dehydroepiandrosterone-sulfate. rhGH resulted in retention of sodium and potassium and a decrease in serum potassium concentration, but neither aldosterone plasma levels nor urinary excretion rates changed until after treatment. During the rhGH washout phase, a natriuresis ensued, but this occurred slowly possibly in part because a higher serum potassium stimulated aldosterone secretion. In summary, short-term treatment with rhGH had no immediate effect on adrenocortical function, but caused pronounced retention of electrolytes. In the posttreatment period, there were increases in aldosterone secretion accompanied by delayed recovery from the retention of sodium.",
keywords = "Adrenal cortex, Aldosterone, Cortisol, Dehydroepiandrosterone-sulfate, Growth hormone",
author = "Pratt, {J. Howard} and Munro Peacock and Henry, {David P.}",
year = "1993",
doi = "10.1159/000139076",
language = "English",
volume = "47",
pages = "36--42",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Effect of recombinant human growth hormone on adrenocortical function, and on sodium and potassium homeostasis

AU - Pratt, J. Howard

AU - Peacock, Munro

AU - Henry, David P.

PY - 1993

Y1 - 1993

N2 - In the present study we examined the effect of treatment with recombinant human growth hormone (rhGH) on adrenocortical secretory function, as well as sodium and potassium balance. rhGH, 100 μg/kg per day, was given for 4 days. Both glucocorticoid and androgen secretion were unaffected by treatment as evidence by unchanged levels of cortisol and dehydroepiandrosterone-sulfate. rhGH resulted in retention of sodium and potassium and a decrease in serum potassium concentration, but neither aldosterone plasma levels nor urinary excretion rates changed until after treatment. During the rhGH washout phase, a natriuresis ensued, but this occurred slowly possibly in part because a higher serum potassium stimulated aldosterone secretion. In summary, short-term treatment with rhGH had no immediate effect on adrenocortical function, but caused pronounced retention of electrolytes. In the posttreatment period, there were increases in aldosterone secretion accompanied by delayed recovery from the retention of sodium.

AB - In the present study we examined the effect of treatment with recombinant human growth hormone (rhGH) on adrenocortical secretory function, as well as sodium and potassium balance. rhGH, 100 μg/kg per day, was given for 4 days. Both glucocorticoid and androgen secretion were unaffected by treatment as evidence by unchanged levels of cortisol and dehydroepiandrosterone-sulfate. rhGH resulted in retention of sodium and potassium and a decrease in serum potassium concentration, but neither aldosterone plasma levels nor urinary excretion rates changed until after treatment. During the rhGH washout phase, a natriuresis ensued, but this occurred slowly possibly in part because a higher serum potassium stimulated aldosterone secretion. In summary, short-term treatment with rhGH had no immediate effect on adrenocortical function, but caused pronounced retention of electrolytes. In the posttreatment period, there were increases in aldosterone secretion accompanied by delayed recovery from the retention of sodium.

KW - Adrenal cortex

KW - Aldosterone

KW - Cortisol

KW - Dehydroepiandrosterone-sulfate

KW - Growth hormone

UR - http://www.scopus.com/inward/record.url?scp=0027180784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027180784&partnerID=8YFLogxK

U2 - 10.1159/000139076

DO - 10.1159/000139076

M3 - Article

C2 - 8337233

AN - SCOPUS:0027180784

VL - 47

SP - 36

EP - 42

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 1

ER -